Neumora Therapeutics Hosts Roundtable on Potential of Navacaprant for Neuropsychiatric Disorders
Aug 15, 2024
Neumora Invest Advisor
Neumora Therapeutics Embarks on Phase 1 Clinical Study for NMRA-266, Targeting Schizophrenia Treatment
Nov 27, 2023